| Shenyang OllyChem Technology Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (24) 6225-9849 +86 13840042106 | |||
![]() |
info@ollychem.com oliverdu@ollychem.com | |||
| Chemical manufacturer since 2001 | ||||
| chemBlink standard supplier since 2007 | ||||
| Simagchem Corporation | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 13806087780 | |||
![]() |
sale@simagchem.com | |||
| Chemical manufacturer since 2002 | ||||
| chemBlink standard supplier since 2008 | ||||
| Taizhou Crene Biotechnology Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (576) 8881-3233 8820-5808 +86 13396860566 | |||
![]() |
order@pharm-intermediates.com | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2011 | ||||
| chemBlink standard supplier since 2009 | ||||
| Zhejiang Ausun Pharmaceutical Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (576) 8558-9335 +86 13957690608 | |||
![]() |
sales@ausunpharm.com | |||
| Chemical manufacturer since 2011 | ||||
| chemBlink standard supplier since 2009 | ||||
| Wilshire Technologies, Inc. | USA | Inquire | ||
|---|---|---|---|---|
![]() |
+1 (609) 683-1117 | |||
![]() |
Wilshire-info@evonik.com | |||
| Chemical manufacturer since 1997 | ||||
| chemBlink standard supplier since 2010 | ||||
| Intatrade Chemicals GmbH | Germany | Inquire | ||
|---|---|---|---|---|
![]() |
+49 (3493) 605-465 | |||
![]() |
sales@intatrade.de | |||
| Chemical distributor | ||||
| chemBlink standard supplier since 2011 | ||||
| Changchun BC&HC Pharmaceutical Technology Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (431) 8087-1788 8087-1588 +86 15804318207 | |||
![]() |
3468242165@qq.com | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2014 | ||||
| chemBlink standard supplier since 2016 | ||||
| Shanghai Yingrui Biopharm Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (21) 3358-5366 3466-6753 +86 13311639313 | |||
![]() |
sales02@shyrchem.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2009 | ||||
| chemBlink standard supplier since 2017 | ||||
| Classification | Flavors and spices >> Synthetic spice >> Lactone and oxygen-containing heterocyclic compound >> Furan and pyran |
|---|---|
| Name | (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one |
| Synonyms | (3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one |
| Molecular Structure | ![]() |
| Molecular Formula | C18H19F3O5 |
| Molecular Weight | 372.34 |
| CAS Registry Number | 53872-60-9 |
| EC Number | 805-964-3 |
| SMILES | C1[C@H]([C@@H]([C@@H]2[C@H]1OC(=O)C2)/C=C/[C@H](COC3=CC=CC(=C3)C(F)(F)F)O)O |
| Hazard Symbols |
| ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Statements | H315-H319-H335-H361-H362 Details | ||||||||||||||||||||||||||||
| Precautionary Statements | P203-P260-P261-P263-P264-P264+P265-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P318-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501 Details | ||||||||||||||||||||||||||||
| Hazard Classification | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| SDS | Available | ||||||||||||||||||||||||||||
|
(+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one is a complex organic compound notable for its unique bicyclic structure and potential applications in medicinal chemistry. The discovery of this compound is rooted in the exploration of structurally diverse bicyclic molecules, which has attracted significant attention due to their potential biological activity and utility in drug development. The molecular architecture of (+)-(3aR,4R,5r,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one features a hexahydrocyclopentafuran moiety that contributes to its rigidity and defines its three-dimensional conformation. The presence of hydroxyl and trifluoromethyl groups introduces polarity and enhances the compound's potential interactions with biological targets. These structural characteristics are significant in determining the compound's reactivity and pharmacological properties. This compound has garnered attention due to its possible applications in treating conditions related to ocular health. Its structural similarity to known ophthalmic agents suggests that it may act as a potent modulator of intraocular pressure, making it a candidate for the management of glaucoma. Research into the pharmacological properties of this compound indicates that it may exhibit prostaglandin-like effects, which could be beneficial in the treatment of ocular hypertension. Furthermore, the presence of the trifluoromethyl group enhances the compound's lipophilicity, facilitating its absorption and distribution within biological systems. This characteristic is particularly advantageous in drug development, where optimizing pharmacokinetics is crucial for the efficacy of therapeutic agents. Studies have indicated that compounds with similar structural features can effectively penetrate biological membranes, allowing for targeted action in specific tissues, such as the eye. The potential applications of (+)-(3aR,4R,5r,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one extend beyond ophthalmology. Its unique structure and reactivity also make it a valuable intermediate in the synthesis of other biologically active compounds. The compound can participate in various chemical transformations, including nucleophilic substitutions and functional group modifications, contributing to the development of new drugs with enhanced therapeutic profiles. In summary, (+)-(3aR,4R,5r,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one is a promising compound in the field of medicinal chemistry, with potential applications in treating ocular diseases and serving as an intermediate for further synthetic development. Ongoing research is focused on elucidating its full pharmacological profile and exploring its utility in various therapeutic contexts, underscoring its significance in advancing drug discovery and development. |
| Market Analysis Reports |
| List of Reports Available for (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one |